Principal Healthcare Innovators ETF (BTEC)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
BTEC Chart
Finding Opportunity in Unloved Healthcare ETFs
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
Principal Healthcare Innovators ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AAL Avraham A. Levitan Glass Jacobson Investment Advisors LLC | 193 | $6,497 | $6,497 | - | - |
Principal Healthcare Innovators ETF (BTEC) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Principal Healthcare Innovators ETF Profile
| - Industry | - Sector | - CEO | NASDAQ (NGS) Exchange | 74255Y409 CUSIP |
| United States Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
The fund is designed to primarily invest in the healthcare sector, focusing on equity securities. With a commitment to allocate at least 80% of its net assets plus any borrowings for investment purposes towards this sector, the fund emphasizes on supporting early-stage companies. These entities typically operate within the realms of healthcare equipment and supplies, pharmaceuticals, biotechnology, and life sciences industries. A distinctive aspect of these investments is their target on companies that are not yet consistently profitable, indicating a strategy that seeks to capitalize on the potential high growth of emerging companies in the healthcare industry.
Products and Services
- Healthcare Equipment and Supplies Investment
Investment in companies that manufacture and distribute healthcare equipment and supplies. This includes a wide range of products such as medical devices, diagnostic tools, and hospital supplies. The focus is on early-stage firms that are innovating within this space, aiming to support the development of new technologies and breakthroughs in medical equipment and supplies.
- Pharmaceuticals Investment
Allocation of funds to early-stage pharmaceutical companies. These are firms engaged in the development, production, and marketing of medications. This segment is characterized by high research and development costs and a long timeline to profitability, driven by the lengthy process of drug development, testing, and regulatory approval. The fund's investment seeks to support the discovery and development of new drugs, potentially addressing unmet medical needs.
- Biotechnology Investment
Funding for biotechnology companies, with a particular interest in early-stage firms. Biotechnology involves the use of living organisms or their systems to develop or make products, particularly in healthcare. This can include the development of novel therapies, genetic research, and biopharmaceuticals. The investment aims to back innovative work in the biotech sector that promises to advance medical science and patient care.
- Life Sciences Investment
Support for companies within the life sciences industry. This field includes, but is not limited to, businesses involved in biomedical research, genomics, and other areas of scientific research related to the biological aspects of life and healthcare. By investing in early-stage life sciences companies, the fund aims to facilitate breakthrough scientific discoveries and the translation of those discoveries into healthcare solutions that can significantly improve patient outcomes and quality of life.
